Contents
Academic literature on the topic 'Parkinson's disease; Nigro-striatal pathway'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Parkinson's disease; Nigro-striatal pathway.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Parkinson's disease; Nigro-striatal pathway"
1
Darbin, Olivier, Xingxing Jin, Christof Von Wrangel, Kerstin Schwabe, Atsushi Nambu, Dean K. Naritoku, Joachim K. Krauss, and Mesbah Alam. "Neuronal Entropy-Rate Feature of Entopeduncular Nucleus in Rat Model of Parkinson’s Disease." International Journal of Neural Systems 26, no. 02 (February 21, 2016): 1550038. http://dx.doi.org/10.1142/s0129065715500380.
Full textAbstract:
The function of the nigro-striatal pathway on neuronal entropy in the basal ganglia (BG) output nucleus, i.e. the entopeduncular nucleus (EPN) was investigated in the unilaterally 6-hyroxydopamine (6-OHDA)-lesioned rat model of Parkinson’s disease (PD). In both control subjects and subjects with 6-OHDA lesion of dopamine (DA) the nigro-striatal pathway, a histological hallmark for parkinsonism, neuronal entropy in EPN was maximal in neurons with firing rates ranging between 15 and 25[Formula: see text]Hz. In 6-OHDA lesioned rats, neuronal entropy in the EPN was specifically higher in neurons with firing rates above 25[Formula: see text]Hz. Our data establishes that the nigro-striatal pathway controls neuronal entropy in motor circuitry and that the parkinsonian condition is associated with abnormal relationship between firing rate and neuronal entropy in BG output nuclei. The neuronal firing rates and entropy relationship provide putative relevant electrophysiological information to investigate the sensory-motor processing in normal condition and conditions such as movement disorders.
2
Pangestiningsih, Tri Wahyu, Woro Danur Wendo, Yulfia Nelymalik Selan, Filphin Adolfin Amalo, Nemay Anggadewi Ndaong, and Victor Lenda. "Histological Features of Catecholaminergic Neuron in Substantia Nigra Induced by Paraquat Dichloride (1,1-dimethyl-4,4 bipyridinium) in Wistar Rat as A Model of Parkinson Disease." Indonesian Journal of Biotechnology 19, no. 1 (December 31, 2015): 91. http://dx.doi.org/10.22146/ijbiotech.8638.
Full textAbstract:
Paraquat dichloride has been used by farmers as a herbicide to kill the grass. On the other hand, paraquatdichloride is harmful if enters to the body, causing Parkinson’s disease, since it is disrupting dopamineproduction in the substantia nigra pars compacta or dopamine pathways Nigro striatal pathway. The studywas done to fi nd out the histological changes of catecholaminergic neurons and Nigro striatal pathway causedby paraquat dichloride treatment in Wistar rats as a model of Parkinson’s disease.Twenty-two Wistar rats 3,5 months old were divided into 4 groups, 5 rats each. Group I (control group)were injected with aquabidest, while groups II, III, and IV were injected intraperitoneally with paraquatdichloride in aquabidest, with the dosage 5 , 10 and 15 mg/kg bw respectively. The rats were injected onceper week for 6 weeks. Three days after the last injection, the rats were anesthetized using xylasin (2 mg/kg)and ketamine (20 mg/kg) intramuscularly, and then were intracardiac perfused using physiological saline asprerinse solution, followed by 10% buffered formalin solution as a fi xative. After animals were fi xed, the brainswere removed and embedded in paraffi n block and cut in 12 μm thickness for immunohistochemistry stainingusing tyrosine hydroxylase antibody. The results of staining then were observed under light microscope andanalyzed descriptively.The results showed that the catecholaminergic neurons were distributed in the substantia nigrapars compacta in all treatment groups, however, the cell density were found decreased only in group IV.Catecholaminergic neurons appear in the bipolar and multipolar form, while dopamine ‘Nigro striatal pathway’was found exist in all treatment groups. From our study, histologycally the decreased of catecholaminergicneurons is only found in rats that received paraquat dichloride in dose 15 mg/kg bw for 6 weeks.
3
Barbagallo, Gaetano, Maria Sierra-Peña, Federico Nemmi, Anne Pavy-Le Traon, Wassilios G. Meissner, Olivier Rascol, and Patrice Péran. "Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease." Movement Disorders 31, no. 3 (December 17, 2015): 325–34. http://dx.doi.org/10.1002/mds.26471.
Full text
4
Hongyan, Zhu, Pei Xiao, Wu Lingyan, Liu Bo, Qi Zeming, and Wang Yuyin. "Synchrotron FTIR Microspectroscopy Study of the Striatum in 6-Hydroxydopamine Rat Model of Parkinson's Disease." Spectroscopy: An International Journal 27 (2012): 229–38. http://dx.doi.org/10.1155/2012/176937.
Full textAbstract:
In the present study, synchrotron-based Fourier transform-infrared (FTIR) microspectroscopy is used to analyze the biochemical composition of the striatal neurons in normal and Parkinson's disease (PD) rat brain tissues. The rat model of Parkinson's disease is established by destroying the nigrostriatal pathway with 6-hydroxydopamine (6-OHDA). The detailed spectral analyses show the significant changes of cellular compositions such as lipids, and proteins in the striatal neurons of 6-OHDA-lesioned PD rats with respect to control neurons. As a result, the intensities of spectral absorption assigned to lipid of the striatal neurons in PD rats are higher than in control animals. Furthermore, the unsaturation levels of phospholipids decrease in PD neurons with respect to control neurons, indicating a high level of lipid peroxidation. The analysis of protein secondary structure shows the significantly higher ratio ofβ-sheet in PD neurons compared to that of control neurons, suggesting that the abnormal protein structure occurs before their morphological appearances in the striatal neurons. These findings suggest that the biochemical changes in neurons could be involved in the pathogenesis of Parkinson's disease.
5
Edwards III, Gamez, Armijo, Kramm, Morales, Taylor-Presse, Schulz, Soto, and Moreno-Gonzalez. "Peripheral Delivery of Neural Precursor Cells Ameliorates Parkinson’s Disease-Associated Pathology." Cells 8, no. 11 (October 30, 2019): 1359. http://dx.doi.org/10.3390/cells8111359.
Full textAbstract:
: Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by loss of motor control due to a wide loss of dopaminergic neurons along the nigro-striatal pathway. Some of the mechanisms that contribute to this cell death are inflammation, oxidative stress, and misfolded alpha-synuclein-induced toxicity. Current treatments are effective at managing the early motor symptoms of the disease, but they become ineffective over time and lead to adverse effects. Previous research using intracerebral stem cell therapy for treatment of PD has provided promising results; however, this method is very invasive and is often associated with unacceptable side effects. In this study, we used an MPTP-injected mouse model of PD and intravenously administered neural precursors (NPs) obtained from mouse embryonic and mesenchymal stem cells. Clinical signs and neuropathology were assessed. Female mice treated with NPs had improved motor function and reduction in the neuroinflammatory response. In terms of safety, there were no tumorigenic formations or any detectable adverse effect after treatment. Our results suggest that peripheral administration of stem cell-derived NPs may be a promising and safe therapy for the recovery of impaired motor function and amelioration of brain pathology in PD.
6
Burbach, J. P. H., P. Cazorla, and M. P. Smidt. "Molecular players in the development and maintenance of mesencephalic dopamine systems." Acta Neuropsychiatrica 11, no. 2 (June 1999): 71–73. http://dx.doi.org/10.1017/s0924270800036206.
Full textAbstract:
Several psychiatric diseases are considered to be neuro-developmental disorders. Amongst these are schizophrenia and autism, in which genetic and environmental components have been indicated. In these disorders intrinsic molecular mechanisms of brain development may be deranged due to genetic predispositions, or modified by external influences. Brain development is a delicate process of well-tuned cellular proliferation and differentiation of multipotent neural progenitor cells driven by spatiotemporal cues. One of the fundamental mechanisms is the interaction between external signals, e.g. growth factors, and internal regulators, e.g. transcription factors. An important transmitter system involved in behavioural and affective functions relevant for psychiatric disorders is the mesencephalic dopamine (DA) system. The mesencephalic DA system is organized in two anatomically and functionally different systems. DA neurons in the ventral tegmental area project to the mesolimbic system and are mostly related to control of behaviour. It has been implicated in drug addiction and affective disorders like dipolar disorder and schizophrenia. The dopamine system of the substantia nigra (nigro-striatal pathway) is implicated in movement control. Degeneration of this system, as in Parkinson's disease, or altered function in tardive dyskinesia have highlighted its importance in human disease. Recent findings in molecular neurobiology have provided the first clues to molecular mechanisms involved in developing and mature DA neurons. These may have clinical implications in novel therapeutic strategies.
7
Morari, Michele, and Martina Fantin. "Loss of the preferential control over the striato-nigral direct pathway by striatal NMDA receptors in a rat model of Parkinson's disease." Analyst 140, no. 11 (2015): 3830–39. http://dx.doi.org/10.1039/c4an01918k.
Full text
8
Anselmi, Laura, Jessica Hampton, Cecilia Bove, and R. Alberto Travagli. "The Nigro-Vagal Pathway is Impaired Prior to Motor Pathways in an Experimental Model of Parkinson's Disease." Gastroenterology 152, no. 5 (April 2017): S925. http://dx.doi.org/10.1016/s0016-5085(17)33156-6.
Full text
9
Kuten, Jonathan, Adi Linevitz, Hedva Lerman, Nanette Freedman, Meir Kestenbaum, Tamara Shiner, Nir Giladi, and Einat Even-Sapir. "[18F] FDOPA PET may confirm the clinical diagnosis of Parkinson's disease by imaging the nigro-striatal pathway and the sympathetic cardiac innervation: Proof-of-concept study." Journal of Integrative Neuroscience 19, no. 3 (2020): 489. http://dx.doi.org/10.31083/j.jin.2020.03.196.
Full text
10
Mehta, V., J. Spears, and I. Mendez. "Neural Transplantation in Parkinson's Disease." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 24, no. 04 (November 1997): 292–301. http://dx.doi.org/10.1017/s0317167100032959.
Full textAbstract:
ABSTRACT:Parkinson's disease is a neurodegenerative disorder that affects about 1% of Canadians between the ages of fifty and seventy. The medical management for these patients consists of drug therapy that is initially effective but has limited long term benefits and does not alter the progressive course of the disease. The recalcitrance of longstanding Parkinson's disease to medical management has prompted the use of alternative surgical therapies. Many neurosurgical procedures have been utilized in order to improve the disabling symptoms these patients harbour. Although most of the current procedures involve making destructive lesions within various basal ganglia nuclei, neural transplantation attempts to reconstitute the normal nigrostriatal pathway and restore striatal dopamine. The initial success of neural transplantation in the rodent and primate parkinsonian models has led to its clinical application in the treatment of parkinsonian patients. Currently, well over one hundred patients throughout the world have been grafted with fetal tissue in an effort to ameliorate their parkinsonian symptoms. Although the results of neural transplantation in clinical trials are promising, a number of issues need to be resolved before this technology can become a standard treatment option. This review focuses on the current status of neural transplantation in Parkinson's disease within the context of other surgical therapies in current use.
Dissertations / Theses on the topic "Parkinson's disease; Nigro-striatal pathway"
1
O'Callaghan, John Francis Xavier. "Mechanisms in neurochemical modulation in the substantia nigra : an electrophysiological study." Thesis, University of Oxford, 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.260149.
Full text
2
Schurig, Katja. "Tissue engineering for reconstructing the central dopaminergic nigro-striatal pathway in Parkinson’s disease: Cutting edge cell culture studies." Doctoral thesis, Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2013. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-112900.
Full textAbstract:
Although neurotransplantation of primary fetal cells into the striatum of patients with Parkinson’s disease (PD) has been reported to be effective, poor clinical outcome and severe side effects lower clinical long-term results. A major drawback of cell replacement therapies in PD is the low cell survival and lacking regeneration of the neuronal circuitries due to the ectopic transplantation of cells into the host striatum. More anatomic and functional integration could potentially be reached by an orthotopic cell transplantation into their natural position within the rostral mesencephalon at the site of the Substantia nigra, where dopaminergic cells get lost in PD. The aim of the thesis was to provide the scientific basis for the use of injectable bioscaffols containing chemo-attractants promoting cell survival, differentiation and axo-dendritic outgrowth of dopaminergic cells. With the so called “bridging” transplantation technology an artificial axon pathway between the substantia nigra and the striatum with targeted nigro-striatal re-innervation should be generated. Thereby, the central dopaminergic nigro-striatal pathway would be reconstructed enabling a fully integration of grafted neurons into the basal ganglia circuitries.
The main focus of the thesis was to explore the influence of bioscaffolds on cell survival and morphology of dopaminergic neurons in vitro. The investigations included isolation of primary fetal mesencephalic cells and fetal mesencephalic neural stem cells (NSCs) from embryonic (E14) mouse brain and their culture on ECM compounds and starPEG-heparin hydrogels. Initial characterizations of the gels showed separate as well as simultaneous immobilization and release of growth factors demonstrating that hydrogels could serve as an efficient storage and delivery system for growth factors. The axo-dendritic outgrowth of dopaminergic cells including primary branching, total branching and neurite elongation; cell survival studies; cell type analysis and cell migration were analyzed by immunostaining.
Both cell sources showed distinct growth properties depending on the stiffness of the gel material and the presence of biomolecules with increased cell survival by the presence of RGD and FGF-2 in the hydrogel independent of network characteristic. Moreover, the presence of RGD on hydrogels was found to initiate differentiation of NSCs, whereas FGF-2 bound to hydrogels was shown to promote the viability of undifferentiated cells. Additionally, survival and axo-dendritic outgrowth of dopaminergic cells were observed to be affected by the gel properties: RGD or FGF-2 modification of hydrogels with intermediate network density showed the best results for dopaminergic growth. With the addition of GDNF to hydrogels the total amount of cells decreased strongly by an equal quantity of dead cells compared to FGF-2 bound hydrogels. Furthermore, differential effects were found for the survival of different brain cells depending on the growth factor which is loaded. GDNF was found to increase the survival of astrocytes, whereas FGF-2 bound to gels stimulated the viability of oligodendrocyte precursor cells. No differential effects were found for the survival of NSCs and mature neuronal cells on GDNF or FGF-2 bound gels. By showing the penetration of primary fetal mesencephalic cells expressing MMPs as endogenous endopeptidases into MMP-cleavable hydrogels, the potential biodegradability of the starPEG-heparin hydrogels was demonstrated.
Together the findings provide the in vitro proof-of-principle data for combining dopaminergic neurons or predopaminergic NSCs with biomaterials for reconstructing the central dopaminergic nigro-striatal pathway by the “bridging” transplantation strategy as an alternative transplantation approach in PD. Further studies should focus on three-dimensional cell culture studies using starPEG-heparin hydrogels with cleavable peptide sequences and their functionalization with gradients of axon guidance molecules to selectively promote dopaminergic outgrowth.
3
Schurig, Katja [Verfasser], Carsten [Akademischer Betreuer] Werner, and Alexander [Akademischer Betreuer] Storch. "Tissue engineering for reconstructing the central dopaminergic nigro-striatal pathway in Parkinson’s disease: Cutting edge cell culture studies / Katja Schurig. Gutachter: Carsten Werner ; Alexander Storch. Betreuer: Carsten Werner ; Alexander Storch." Dresden : Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2013. http://d-nb.info/1068152168/34.
Full text
4
Kalaani, Joanna. "Molecular guidance of dopaminergic cells transplanted in a mouse model of Parkinson's disease." Thesis, Poitiers, 2016. http://www.theses.fr/2016POIT2252/document.
Full textAbstract:
La maladie de Parkinson (MP) est caractérisée par une dégénérescence des neurones dopaminergiques de la voie nigrostriée. La thérapie cellulaire, par transplantation intranigrale de cellules fœtales issues de mésencéphale ventral (MV), assure un rétablissement anatomique et fonctionnel de cette voie. Des molécules de guidage axonal (MGA) joueraient ainsi un rôle dans la reconnexion axonale des cellules transplantées. Pour tester cette hypothèse, nous avons étudié l'expression de MGA dans le cerveau adulte intact et dans des cellules destinées à la transplantation, ainsi que dans le cerveau adulte d'un modèle murin de la MP après transplantation. Dans le tissu intact, nous avons montré que semaphorin7A (Sema7A) et Sema3A et leurs récepteurs, plexinC1 et neuropilin1, conservent leur expression protéique. De plus, grâce à l'utilisation de puces à ADN, nous avons montré que les récepteurs Robo2, neuropilin1, neuropilin2, EphA5 et DCC sont exprimés de manière différentielle dans les deux populations cellulaires utilisées pour la transplantation. Ceci suggère que ces molécules seraient impliquées dans la restauration fonctionnelle observée. Enfin, dans le tissu lésé, nous avons observé, par RT-qPCR, des variations d'expression de l'ARNm de ces MGA après transplantation intranigrale des cellules fœtales du MV, suggérant plus particulièrement l'implication de Sema3A, Sema3F et Sema7A dans la reconstruction de la voie. Ce travail met en lumière l'action de sémaphorines dans le guidage axonal des cellules transplantées. L'intégration de ces MGA dans les procédures de transplantation pourrait aider à optimiser les procédures de thérapie cellulaire dans la MPParkinson's disease (PD) is characterised by the degeneration of the dopaminergic nigrostriatal pathway. Cell therapy using intranigral transplantation of foetal ventral mesencephalon (VM) cells in a mouse model of PD results in anatomical and functional reconstruction of the pathway. This suggests a role for axon guidance molecules (GMs) in reconnecting transplanted cells to their striatal target. To test this hypothesis, we studied the expression of axon GMs in the intact adult brain, on cells used for transplantation and in a mouse model of PD after cell therapy. In the intact brain, we showed that GMs as semaphorin7A (Sema7A) and Sema3A and their corresponding receptors, plexinC1 and neuropilin1, retain an expression at the protein level, therefore showing a possible role for these guidance cues in the adult brain. Moreover, using microarray, we studied GM receptor expression profiles in two types of cells used for transplantation and exhibiting different functional ameliorations. Robo2, neuropilin1, neuropilin2, EphA5 and DCC receptors showed differential expression between the two cellular populations, indicating their possible contribution to the different functional outcomes observed. In the lesioned mouse brain, we observed, using RT-qPCR, variations of mRNA expression of these axon GMs after intranigral transplantation of foetal VM derived cells, thus suggesting the implication of Sema3A, Sema3F, and Sema7A in the reconstruction of the pathway. Overall, this work highlights particular importance of semaphorins in the nigrostriatal pathway reconstruction. Integrating these cues in transplantation procedures can possibly optimize cell therapy for PD patients
5
Schurig, Katja. "Tissue engineering for reconstructing the central dopaminergic nigro-striatal pathway in Parkinson’s disease: Cutting edge cell culture studies." Doctoral thesis, 2011. https://tud.qucosa.de/id/qucosa%3A26874.
Full textAbstract:
Although neurotransplantation of primary fetal cells into the striatum of patients with Parkinson’s disease (PD) has been reported to be effective, poor clinical outcome and severe side effects lower clinical long-term results. A major drawback of cell replacement therapies in PD is the low cell survival and lacking regeneration of the neuronal circuitries due to the ectopic transplantation of cells into the host striatum. More anatomic and functional integration could potentially be reached by an orthotopic cell transplantation into their natural position within the rostral mesencephalon at the site of the Substantia nigra, where dopaminergic cells get lost in PD. The aim of the thesis was to provide the scientific basis for the use of injectable bioscaffols containing chemo-attractants promoting cell survival, differentiation and axo-dendritic outgrowth of dopaminergic cells. With the so called “bridging” transplantation technology an artificial axon pathway between the substantia nigra and the striatum with targeted nigro-striatal re-innervation should be generated. Thereby, the central dopaminergic nigro-striatal pathway would be reconstructed enabling a fully integration of grafted neurons into the basal ganglia circuitries.
The main focus of the thesis was to explore the influence of bioscaffolds on cell survival and morphology of dopaminergic neurons in vitro. The investigations included isolation of primary fetal mesencephalic cells and fetal mesencephalic neural stem cells (NSCs) from embryonic (E14) mouse brain and their culture on ECM compounds and starPEG-heparin hydrogels. Initial characterizations of the gels showed separate as well as simultaneous immobilization and release of growth factors demonstrating that hydrogels could serve as an efficient storage and delivery system for growth factors. The axo-dendritic outgrowth of dopaminergic cells including primary branching, total branching and neurite elongation; cell survival studies; cell type analysis and cell migration were analyzed by immunostaining.
Both cell sources showed distinct growth properties depending on the stiffness of the gel material and the presence of biomolecules with increased cell survival by the presence of RGD and FGF-2 in the hydrogel independent of network characteristic. Moreover, the presence of RGD on hydrogels was found to initiate differentiation of NSCs, whereas FGF-2 bound to hydrogels was shown to promote the viability of undifferentiated cells. Additionally, survival and axo-dendritic outgrowth of dopaminergic cells were observed to be affected by the gel properties: RGD or FGF-2 modification of hydrogels with intermediate network density showed the best results for dopaminergic growth. With the addition of GDNF to hydrogels the total amount of cells decreased strongly by an equal quantity of dead cells compared to FGF-2 bound hydrogels. Furthermore, differential effects were found for the survival of different brain cells depending on the growth factor which is loaded. GDNF was found to increase the survival of astrocytes, whereas FGF-2 bound to gels stimulated the viability of oligodendrocyte precursor cells. No differential effects were found for the survival of NSCs and mature neuronal cells on GDNF or FGF-2 bound gels. By showing the penetration of primary fetal mesencephalic cells expressing MMPs as endogenous endopeptidases into MMP-cleavable hydrogels, the potential biodegradability of the starPEG-heparin hydrogels was demonstrated.
Together the findings provide the in vitro proof-of-principle data for combining dopaminergic neurons or predopaminergic NSCs with biomaterials for reconstructing the central dopaminergic nigro-striatal pathway by the “bridging” transplantation strategy as an alternative transplantation approach in PD. Further studies should focus on three-dimensional cell culture studies using starPEG-heparin hydrogels with cleavable peptide sequences and their functionalization with gradients of axon guidance molecules to selectively promote dopaminergic outgrowth.